Forward Looking Statements

Our discussion during this presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates and our oncology strategy, including their potential benefits, and expected clinical trial study starts, regulatory submissions, regulatory approvals and product launches that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.
Pfizer's Oncology Strategy, Pipeline and Portfolio

**Pfizer Oncology: Today and in the Future**

**Growing Product Line**
- Aromasin
- Sutent
- Torisel
- Mylotarg (Japan only)

**Launches in 4 Years**
- Ibrance
- Xalkori
- Inlyta
- Bosulif

---

**PIPELINE**

**Early-Stage Pipeline**
- Targeting the Immune System: Immuno-Oncology
  - Avelumab (PD-L1)
  - 4-1BB
  - OX-40
  - CCR2
  - VIBR

- Targeting the Tumor: Small Molecules
  - Gefitinib (PI3K/mTOR IV)
  - Lorlatinib (ALK/ROS1)
  - Palbociclib

- Targeting the Tumor: Antibody-Drug Conjugates
  - Notch 3 ADC
  - TROP2 ADC
  - PTK7 ADC
  - P-Cadherin (bi-specific)

**Growing Late-Stage Portfolio**
- Palbociclib
  - mBC / High-Risk eBC
- Axitinib
  - mRCC Adj
- Avelumab (PD-L1)
  - NSCLC

---

**PALOMA-1**
- 1L ER+, HER2- Adv BC

**PALOMA-2**
- 1L ER+, HER2- Adv BC

**PALLAS**
- ER+ eBC (Stages II-III)

**PELOPE-B**
- Recurrent ER+, HER2- Adv BC

**PEARL**
- Recurrent ER+, HER2- Adv BC

**Additional Trials**
- NSCLC: Notch 3 ADC, TROP2 ADC, PTK7 ADC
- Prostate cancer VBIR
- CML 1L

---

**Targeting the Immune System: A New Front in the War on Cancer**

- Checkpoint modulators
  - PD-L1 avelumab
  - 4-1BB, OX40

- Adoptive T-cell CAR-T approaches

- Small molecules
  - IDO/TDO inhibitors

- Vaccines
  - Prostate cancer VBIR

---

**Targeting the Tumor**

**Signaling Networks**

**Metabolic Networks**

**Epigenetic Networks**

---

**Innovative Modalities Support Strategy and Drive Future of Therapies**

- NCEs
- mAbs
- ADCs
- Bi-specifics
- Vaccines
- CAR-T

---

**KEY:**
- ADR: Antibody Drug Conjugate
- CAR-T: Chimeric Antigen Receptor T-Cell
- eBC: Early Breast Cancer
- mBC: Metastatic Breast Cancer
- NCEs: New Chemical Entities
- NSCLC: Non-Small Cell Lung Cancer
- RCC: Renal Cell Carcinoma
- TCR: T-Cell Receptor
- HNSCC: Head and Neck Squamous Cell Carcinoma

---

Ibrance Brand Vision

---

DRAFT – Subject to Further Review – Company Confidential and Proprietary – Internal Use Only
Pfizer Oncology: An Exciting Road Ahead

• Excellent uptake of Ibrance reaching over 12,000 patients since February 2015 launch

• Our goal is to deliver 1-2 new product launches a year for next 3 years as well as potential indication expansions for Bosuilib, Xalkori and Ibrance

• In addition, we will aim for 7-9 pivotal study starts in 2015 and 3-5 a year for next 3 years

• 5 IO compounds in the clinic in 2015 and the potential to have up to 10 in 2016

• Uniquely positioned in immuno-oncology with breadth of portfolio and combination strategy
Immuno-Oncology

Chris Boshoff, VP, Early Development, Translational, & Immuno-Oncology
Pfizer is focused on a multi-pronged approach to IO

**Focused Single Agent Program**
- Accelerated development for target tumors: PD1, PDL1, 41BB
- Enable rapid advancement to combination strategies

**Advance Focused Single Agent Program**

**Breadth and Depth of Our Portfolio Offers Potential for Several IO Combos**
- Pfizer will have five IO agents in development this year: PD-L1, 4-1BB, OX40, CCR2 and VIBR
- Multiple ADCs and range of small molecules for potential combinations
- Anticipated combinations with avelumab in 2015 include: +ALK/ROS; + Inlyta; + 4-1BB

**Expand Portfolio Through Acquisitions and/or Collaborations**
- Strengthen portfolio, grow scientific expertise; such as CAR-T (Cellectis) and IDO1 (iTEOS)

**Pfizer IO Strategy**

- **Focused Single Agent Program**
- **Broad Range of Portfolio Combinations**
- **Grow PFE IO Footprint with BD**
Pfizer’s Pipeline Targets Multiple Immune Mechanisms

**Checkpoint inhibitors**
- Anti-PD-L1 avelumab (Ph 3 with Merck KGaA)
- Anti-PD-1 PF-06801591 (IND ‘15)

**Activate T cells**
- CD137/4-1BB (Ph 1)
- OX-40 agonist antibody (Ph 1)

**Deplete Treg cells**
- CCR4 antibody mogamulizumab (Ph 1 with Kyowa Hakko Kirin Pharma)

**Abrogate suppression from macrophages & MDSCs**
- M-CSF antibody PD-0360324 (Ph 1)
- CCR2 inhibitor PF-04136309 (Ph 1)
- IDO1/TDO2 inhibitors (Preclinical)

**Transfer engineered T cells**
- Allogeneic CAR-T (Preclinical with Cellectis)
Rational Combinations

Our Immunotherapy Portfolio

- OX40 mAb
- 4-1BB mAb
- KHK: CCR4 mAb
- CCR2i
- VBIR
- M-CSF mAb
- 4-1BB mAb
- 4-1BB mAb
- 4-1BB mAb

Our Kinase Inhibitors

- Chemotherapy
- Inlyta (axitinib)
- XALKORI (crizotinib)
- gedatolisib (PI3K/mTOR)
- EGFR T790M
- IBRANCE (palbociclib)
- glasdegib / SMO
- Sutent
- ALK/ROS
- External Combos
- Keytruda
- Faslodex
- letrozole
- IMBRUVICA
- tasilisib
- ruxolitinib
- azacitidine

Ongoing or Planned Studies

- 4-1BB mAb
- KHK: CCR4 mAb
- avelumab
- vBIR
- M-CSF mAb
- 4-1BB mAb
- 4-1BB mAb
- 4-1BB mAb

Potential Future Studies

- KHK: CCR4 mAb
- avelumab

ADC

Inotuzumab + Other
Avelumab (anti-PD-L1)

Potential to Elicit Antibody-Mediated Cell Cytotoxicity (ADCC)

Key Competitors

- DURVALUMAB
- ATEZOLIZUMAB
- OPDIVO
- KEYTRUDA
• The JAVELIN Clinical Trial Program is assessing the safety and efficacy of Avelumab across multiple tumor types

• >1,000 patients treated as part of multicenter, dose-escalation and parallel-group, dose-expansion phase I trial (NCT01772004; JAVELIN Solid Tumor)

• Avelumab efficacy and safety are being investigated in various tumor types; similar profile to competitors

• Efficiency and effective decision-making in program design and implementation

### JAVELIN Solid Tumor: Phase I Study 2015 (EMR 100070-001)

#### Completed Efficacy
- NSCLC 2L
- Gastric Cancer
- mBreast Cancer
- NSCLC 1L

#### Signal Detection
- CRC
- CRPC
- Ovarian Cancer
- Melanoma
- Bladder
- Mesothelioma
- Adrenocortical
- RCC

#### Expanded Efficacy
- Ovarian
- Bladder
- Head and Neck
- Gastric 3L
- RCC 1L & 2L
### JAVELIN Clinical Development Program Across 15 Tumor Types

**Ongoing Trials (as of October 1, 2015)**

<table>
<thead>
<tr>
<th>Trial Type</th>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>avelumab monotherapy: JAVELIN solid tumor trial</td>
<td>NSCLC 1L/2L</td>
</tr>
<tr>
<td>Metastatic Breast Cancer</td>
<td>Gastric/ (GEJ) 1L/3L</td>
</tr>
<tr>
<td>Castrate Resistant Prostate Cancer</td>
<td>Colorectal Cancer</td>
</tr>
<tr>
<td></td>
<td>Urothelial/Bladder Cancer</td>
</tr>
<tr>
<td></td>
<td>Ovarian Cancer</td>
</tr>
<tr>
<td></td>
<td>Mesothelioma</td>
</tr>
<tr>
<td></td>
<td>Adrenocortical Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Melanoma</td>
</tr>
<tr>
<td></td>
<td>SCCHN</td>
</tr>
<tr>
<td></td>
<td>Renal Cell Carcinoma 1L/2L</td>
</tr>
</tbody>
</table>

**Trials initiating over next 6 months (October 2015 – March 2016)**

1. **avelumab + Inlyta**
   - Renal Cell Carcinoma 1L
   - NSCLC ALK+ 1L
2. **avelumab + Xalkori / lorlatinib**
   - NSCLC, SCCHN, Melanoma
3. **avelumab monotherapy**
   - Merkel Cell Carcinoma 1L
   - NSCLC 1L
   - SCCHN 2L
   - Hodgkins Lymphoma
4. **avelumab + chemo**
   - Bladder Cancer 1L Sequential Therapy
   - Gastric Cancer 1L
   - Gastric Cancer 3L Sequential Therapy
   - Ovarian Cancer Platinum Resistant/Refractory
   - Ovarian Platinum Sensitive 1L

---

**KEY:**

- **Phase I / IB**
- **Phase II**
- **Phase III**

---

• Progress year-to-date represents robust program across more than 15 tumor types and lines of therapy.

• By the end of 2015, we plan to initiate up to 6 pivotal studies.

• By ASCO 2016, we expect JAVELIN clinical program will include up to 25 trials studying avelumab as single agent and combination therapy.

• If successful, first potential commercial launch for avelumab anticipated in 2017. We expect at least one or more additional launches each year through 2022.
CD137/4-1BB Mechanism of Action

**Urelumab (BMS 663513)**

- IgG4; $t_{1/2} \sim 8-12h$; Q3W
- Does not block natural ligand

**PF-05082566**

- IgG2; $t_{1/2} \sim 10h$; Q4W
- Ligand binding blocker
Rituxan + PF-2566
Durable CR in Heavily Pretreated R-refractory FL

Screen

Month 2

0.12 mg/kg
PF-2566

Date of Diagnosis
RCVP
Rituxan
Bendamustine
Rituxan
Rituxan
Idelalisib
Bexxar
PF-2566 +Rituxan

CR
PD
PR
PD
PR
PD
PD
CR

>26 mo
Thank You